Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma

Fig. 5

Upregulation of EFNA3 in lung adenocarcinoma (LUAD) tissues and its relationship with clinicopathological features and outcomes. A Representative images of EFNA3 staining in LUAD tissue and paired normal lung tissue; B The IHC score of EFNA3 was significantly increased in LUAD tissues; EFNA3 staining score increased significantly with tumor size (C), lymph node metastasis (D) and advanced TNM stages (E); F Kaplan–Meier survival analysis and log-rank tests showed that high expression levels of EFNA3 were associated with poor prognosis (P = 0.001)

Back to article page